Using videotelephony to support paediatric oncology-related palliative care in the home: from abandoned RCT to acceptability study.

Autor: Bensink ME, Armfield NR, Pinkerton R, Irving H, Hallahan AR, Theodoros DG, Russell T, Barnett AG, Scuffham PA, Wootton R

Publikováno v: Palliative Medicine; Apr2009, Vol. 23 Issue 3, p228-237, 10p

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.

Autor: Urman R; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA. rurman@amgen.com., Princic N; Merative, Ann Arbor, MI, USA., Vuvu F; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Patel LB; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Oh S; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Chandler D; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Hindiyeh N; Independent Consultant, San Diego, CA, USA., Bensink ME; Benofit Consulting, Brisbane, QLD, Australia.

Publikováno v: Pain and therapy [Pain Ther] 2024 Oct; Vol. 13 (5), pp. 1299-1313. Date of Electronic Publication: 2024 Aug 23.

Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study.

Autor: Multani JK; IQVIA, Falls Church, Virginia, USA., Urman R; Amgen Inc., Thousand Oaks, California, USA., Park AS; Amgen Inc., Thousand Oaks, California, USA., Gill K; Amgen Inc., Thousand Oaks, California, USA., Vuvu F; Amgen Inc., Thousand Oaks, California, USA., Sun K; IQVIA, Falls Church, Virginia, USA., Patel LB; Amgen Inc., Thousand Oaks, California, USA., Stockl KM; IQVIA, Falls Church, Virginia, USA., Hawkins K; IQVIA, Falls Church, Virginia, USA., Rhyne C; Diamond Headache Clinic, Chicago, Illinois, USA., Bensink ME; Benofit Consulting, Brisbane, Queensland, Australia.

Publikováno v: Headache [Headache] 2024 Sep 09. Date of Electronic Publication: 2024 Sep 09.

Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with FSGS in a US Real-World Database.

Autor: Velez JCQ; Department of Nephrology, Ochsner Health, New Orleans, Louisiana.; Ochsner Clinical School, The University of Queensland, Brisbane, Queensland, Australia., Thakker KM; Notting Hill Consulting LLC, Celebration, Florida., Bensink ME; Travere Therapeutics, Inc., San Diego, California., Lerma EV; University of Illinois Chicago/Advocate Christ Medical Center, Oak Lawn, Illinois., Lieblich R; VJA Consulting, Walnut Creek, California., Bunke CM; CM Bunke Consulting, Mt. Pleasant, South Carolina., Gong W; Travere Therapeutics, Inc., San Diego, California., Wang K; Travere Therapeutics, Inc., San Diego, California., Rava AR; Genesis Research Group, Hoboken, New Jersey., Amari DT; Genesis Research Group, Hoboken, New Jersey., Oliveri D; Genesis Research Group, Hoboken, New Jersey., Murphy MV; Genesis Research Group, Hoboken, New Jersey., Cork DMW; Genesis Research Group, Newcastle upon Tyne, United Kingdom.

Publikováno v: Kidney360 [Kidney360] 2024 Aug 01; Vol. 5 (8), pp. 1145-1153. Date of Electronic Publication: 2024 May 15.

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden.

Autor: Bensink ME; Travere Therapeutics, Inc, San Diego, CA., Goldschmidt D; Analysis Group, Boston, MA., Zhou ZY; Analysis Group, Boston, MA., Wang K; Travere Therapeutics, Inc, San Diego, CA., Lieblich R; VJA Consulting, Walnut Creek, CA., Bunke CM; CM Bunke Consulting, Mt. Pleasant, SC.

Publikováno v: Kidney medicine [Kidney Med] 2023 Nov 27; Vol. 6 (2), pp. 100760. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2024).